Genscript Biotech (1548) Fundamentals 2026 — Revenue Analysis | SniperIQ
Genscript Biotech (1548) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Genscript Biotech (1548) has a market capitalization of approximately HK
Genscript Biotech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Genscript Biotech runs a net profit margin of -55.5%, a gross margin of 57.7%, and an operating margin of 26.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Genscript Biotech reported revenue of $960M for fiscal year 2025, with net income of -$533M and earnings per share (EPS) of -0.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Genscript Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Genscript Biotech carries a debt-to-equity ratio of 0.07x and a current ratio of 1.47x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Genscript Biotech (1548) the key facts are: market cap HK
Get Genscript Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.